PLEKHA3

Across TCGA pan-cancer cohorts, PLEKHA3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLEKHA3 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher PLEKHA3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLEKHA3 expression acts as an unfavorable survival marker.

KIRC, SARC, and LUSC are the cancer types where PLEKHA3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.181	0.655	.046	6	view →
SARC	OS	Median	All	0.156	0.767	.001	6	view →
LUSC	OS	Median	II,III,IV	0.279	0.742	.032	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLEKHA3–KIRC (OS)

Open the KIRC breakdown →